Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5334-5338

  Shao, Pengcheng P ^a   Ye, Feng ^a   Weber, Ann E ^a   Li, Xiaohua ^a   Lyons, Kathryn A ^a   Parsons, William H ^a   Garcia, Maria L ^a   Priest, Birgit T ^a   Smith, McHardy M ^a   Felix, John P ^a   Williams, Brande S ^a   Kaczorowski, Gregory J ^a   McGowan, Erin ^a   Abbadie, Catherine ^a   Martin, William J ^a   McMasters, Daniel R ^a   Gao, Ying Duo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amide replacement; Heterocycles; Inflammatory pain; Isoxazole; Neuropathic pain; Voltage gated sodium channel blocker

Indexed keywords

CDA 54; ISOXAZOLE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CHRONIC PAIN; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; RAT;

ANIMALS; CELL LINE; CHRONIC DISEASE; HUMANS; ISOXAZOLES; PAIN; RATS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; SPINAL NERVES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68949109982     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.135     Document Type: Article

References (13)

1. Shao P.P., Ye F., Weber A.E., Li X., Lyons K.A., Parsons W.H., Garcia M.L., Priest B.T., Smith M.M., Felix J.P., Williams B.S., Kaczorowski G.J., McGowan E., Abbadie C., Martin W.J., McMasters D.R., and Gao Y.-D. Bioorg. Med. Chem. Lett. 19 (2009) 5329
2. Ellman J.A., Owens T.D., and Tang T.P. Acc. Chem. Res. 35 (2002) 984
3. Shao P.P., and Ye F. Tetrahedron Lett. 49 (2008) 3554
4. Clark J.H. Chem. Rev. 80 (1980) 429
5. Grundmann C. Synthesis 7 (1970) 344
6. Geny A., Leboeuf D., Rouquie G., Vollhardt K., Peter C., Malacria M., Gandon V., and Aubert C. Chem.-A Eur. J. 13 (2007) 5408
7. Felix J.P., Williams B.S., Priest B.T., Brochu R.M., Dick I.E., Warren V.A., Yan L., Slaughter R.S., Kaczorowski G.J., Smith M.L., and Garcia M.L. Assay Drug Dev. Tech. 2 (2004) 260
8. Wang J., Della Penna K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., Bennett P.B., and Salata J.J. Am. J. Physiol. Heart Circ. Physiol. 284 (2002) H256
9. Torsional energy profiles of the substituted N-benzylacetamide model systems in which the cyclopentane-phenylisoxazole was truncated to a methyl group were calculated using MacroModel (Schrödinger, Portland, OR). The MMFFs force field was employed with a distance-dependent dielectric of 4r. The torsions were driven both forward and backward, and the lowest energy at each dihedral angle was taken. For the spirocyclopentyl and spirocyclohexyl analogs, two puckers of the carbocycle were used.
10. Rat PK experiments were conducted as follows: Test compounds were typically formulated as 1.5 mg/mL solutions in mixtures of PEG300/water or DMSO/PEG300/water. Fasted male Sprague-Dawley rats were given either a 1.0 mg/kg iv dose of test compound solution via a cannula implanted in the femoral vein (n = 3) or a 3.0 mg/kg po dose by gavage (n = 3). Serial blood samples were collected at 5 (iv only), 15, and 30 min, and at 1, 2, 4, 6, and 8 h post dose. Plasma was collected by centrifugation, and plasma concentrations of test compound were determined by LC-MS/MS following protein precipitation with acetonitrile.
11. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. J. Neurosci. Methods 53 (1994) 55
12. Shao P., Ok D., Fisher M.H., Garcia M.L., Kaczorowski G.J., Li C., Lyons K.A., Martin W.J., Meinke P.T., Priest B.T., Smith M.M., Wyvratt M.J., Ye F., and Parsons W.H. Bioorg. Med. Chem. Lett. 15 (2005) 1901
13. Brochu R.M., Dick I.E., Tarpley J.W., McGowan E., Gunner D., Herrington J., Shao P., Ok D., Li C., Parsons W.H., Stump G.L., Regan C.P., Lynch Jr. J.J., Lyons K.A., McManus O.B., Clark S., Ali Z., Kaczorowski G.J., Martin W.J., and Priest B.T. Mol. Pharmacol. 69 (2006) 823